

1 November 2013

Meindert Boysen
Programme Director, Technology Appraisals
Centre for Health Technology Evaluation
NICE
Level 1A, City Tower
Piccadilly Plaza
Manchester M1 4BT

By email

Dear Mr Boysen

Health Technology Appraisal: Review of TA75; Interferon alfa and ribavirin for treating chronic hepatitis C, TA106; Peginterferon alfa and ribavirin for treating mild hepatitis C, and TA200; Pegylated interferons, peginterferon alfa, ribavirin and alfa interferon for treating hepatitis C – Proposal to move the existing guidance to the static list


Thank you for inviting the British HIV Association (BHIVA) to comment on the above health technology appraisal. The Association fully supports the NICE assessment that there is no new evidence that would lead to a change in the existing recommendations for TA75, TA106 or TA200. BHIVA also supports the NICE recommendations for the use of peginterferons and ribavirin being now very fragmented, and that it would be beneficial to bring all of the existing recommendations together in the context of wider clinical practice; and that the best place for this to take place would be within a clinical guideline.

BHIVA also agrees that there is no evidence to warrant an update within the technology appraisals programme and that TA200 should be moved to the static list of technology appraisals, and that TA75 and TA106 should remain on the static list until any new data are available.

BHIVA has NICE-accredited process *Guidelines for the management of hepatitis viruses in adults infected with HIV 2013*, which have recently been published¹ and many of these points are covered within these guidelines.

With kind regards

Yours sincerely



Dr Ranjababu Kulasegaram
Chair, BHIVA Hepatitis Society Executive Panel



Professor Mark Nelson
Vice-Chair, BHIVA Hepatitis Society Executive Panel

¹ *HIV Medicine* (2013), **14** (Suppl. 4), 1–71 and <http://www.bhiva.org/hepatitis-2013.aspx>